α3 MICA/B iNK cells (GT Biopharma/Fate Therapeutics)

N/A

Report date: 2024/04/02 13:41:31

Base Information

Drug Nameα3 MICA/B iNK cells (GT Biopharma/Fate Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionAnti-MICAAnti-MICB
TargetsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence B
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGt Biopharma IncFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics IncGt Biopharma Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A